PURPOSE: Cutaneous T-cell lymphoma (CTCL) is an uncommon extranodal non-Hodgkin T-cell lymphoma that originates from mature T lymphocytes homed at the skin. Epigenetic alterations observed in CTCL are not limited to overexpression of Histone Deacetylases but also to DNA hypermethylation. The known synergy between Histone deacetylase inhibitors (HDACi) and DNA methyltransferases inhibitors (DNMTi) suggests that combining these agent classes could be effective for CTCL. METHODS: In this study, the combinations of the HDACi and DNMTi hydralazine/valproate (HV) and vorinostat/decitabine (VD) were compared in regard to viability inhibition, clonogenicity, pharmacological interaction and cell cycle effects in the CTCL cell line Hut78. In addition, the effect of these combinations was evaluated in normal peripheral blood mononuclear cells. RESULTS: The results show that each of the DNMTi and HDACi exerts growth inhibition, mostly by inducing apoptosis as shown in the cell cycle distribution. However, in the combination of HV the interaction is more synergic and also it inhibits the clonogenic capacity of cells over time. Additionally, the HV combination seems to affect in a minor degree the viability of peripheral blood mononuclear cells. CONCLUSIONS: The results of this study and the preclinical and clinical evidence on the efficacy of combining HDACi with DNMTi strongly suggest that more studies are needed with this drug class combination in CTCL, particularly with the hydralazine-valproate scheme, which is safe, and these drugs are widely available and administered by oral route.
PURPOSE:Cutaneous T-cell lymphoma (CTCL) is an uncommon extranodal non-Hodgkin T-cell lymphoma that originates from mature T lymphocytes homed at the skin. Epigenetic alterations observed in CTCL are not limited to overexpression of Histone Deacetylases but also to DNA hypermethylation. The known synergy between Histone deacetylase inhibitors (HDACi) and DNA methyltransferases inhibitors (DNMTi) suggests that combining these agent classes could be effective for CTCL. METHODS: In this study, the combinations of the HDACi and DNMTi hydralazine/valproate (HV) and vorinostat/decitabine (VD) were compared in regard to viability inhibition, clonogenicity, pharmacological interaction and cell cycle effects in the CTCL cell line Hut78. In addition, the effect of these combinations was evaluated in normal peripheral blood mononuclear cells. RESULTS: The results show that each of the DNMTi and HDACi exerts growth inhibition, mostly by inducing apoptosis as shown in the cell cycle distribution. However, in the combination of HV the interaction is more synergic and also it inhibits the clonogenic capacity of cells over time. Additionally, the HV combination seems to affect in a minor degree the viability of peripheral blood mononuclear cells. CONCLUSIONS: The results of this study and the preclinical and clinical evidence on the efficacy of combining HDACi with DNMTi strongly suggest that more studies are needed with this drug class combination in CTCL, particularly with the hydralazine-valproate scheme, which is safe, and these drugs are widely available and administered by oral route.
Authors: Anastasios Stathis; Sebastien J Hotte; Eric X Chen; Holger W Hirte; Amit M Oza; Patricia Moretto; Sheila Webster; Anne Laughlin; Lee-Anne Stayner; Shauna McGill; Lisa Wang; Wen-jiang Zhang; Igor Espinoza-Delgado; Julianne L Holleran; Merrill J Egorin; Lillian L Siu Journal: Clin Cancer Res Date: 2011-01-28 Impact factor: 12.531
Authors: Katherine B Chiappinelli; Pamela L Strissel; Alexis Desrichard; Huili Li; Christine Henke; Benjamin Akman; Alexander Hein; Neal S Rote; Leslie M Cope; Alexandra Snyder; Vladimir Makarov; Sadna Budhu; Sadna Buhu; Dennis J Slamon; Jedd D Wolchok; Drew M Pardoll; Matthias W Beckmann; Cynthia A Zahnow; Taha Merghoub; Taha Mergoub; Timothy A Chan; Stephen B Baylin; Reiner Strick Journal: Cell Date: 2015-08-27 Impact factor: 41.582
Authors: Yago Nieto; Benigno C Valdez; Peter F Thall; Roy B Jones; Wei Wei; Alan Myers; Chitra Hosing; Sairah Ahmed; Uday Popat; Elizabeth J Shpall; Muzaffar Qazilbash; Alison Gulbis; Paolo Anderlini; Nina Shah; Qaiser Bashir; Amin Alousi; Yasuhiro Oki; Michelle Fanale; Bouthaina Dabaja; Chelsea Pinnix; Richard Champlin; Borje S Andersson Journal: Cancer Date: 2016-05-20 Impact factor: 6.860
Authors: Michael J Burke; Jatinder K Lamba; Stanley Pounds; Xueyuan Cao; Yogita Ghodke-Puranik; Bruce R Lindgren; Brenda J Weigel; Michael R Verneris; Jeffrey S Miller Journal: Am J Hematol Date: 2014-06-27 Impact factor: 10.047
Authors: Sima Rozati; Phil F Cheng; Daniel S Widmer; Kazuyasu Fujii; Mitchell P Levesque; Reinhard Dummer Journal: Clin Cancer Res Date: 2015-12-09 Impact factor: 12.531
Authors: S J Garcés-Eisele; B Cedillo-Carvallo; V Reyes-Núñez; L Estrada-Marín; R Vázquez-Pérez; M Juárez-Calderón; M O Guzmán-García; A Dueñas-González; A Ruiz-Argüelles Journal: J Clin Pharm Ther Date: 2014-04-04 Impact factor: 2.512
Authors: Claudia Arce; Carlos Pérez-Plasencia; Aurora González-Fierro; Erick de la Cruz-Hernández; Alma Revilla-Vázquez; Alma Chávez-Blanco; Catalina Trejo-Becerril; Enrique Pérez-Cárdenas; Lucia Taja-Chayeb; Enrique Bargallo; Patricia Villarreal; Teresa Ramírez; Teresa Vela; Myrna Candelaria; Maria F Camargo; Elizabeth Robles; Alfonso Dueñas-González Journal: PLoS One Date: 2006-12-20 Impact factor: 3.240
Authors: K Eurídice Juárez-Mercado; Fernando D Prieto-Martínez; Norberto Sánchez-Cruz; Andrea Peña-Castillo; Diego Prada-Gracia; José L Medina-Franco Journal: Pharmaceuticals (Basel) Date: 2020-12-27